Literature DB >> 32767064

Sexual activity and function in women with advanced stages of pelvic organ prolapse, before and after laparoscopic or vaginal mesh surgery.

Sònia Anglès-Acedo1, Cristina Ros-Cerro2, Sílvia Escura-Sancho1, M José Palau-Pascual1, Eduardo Bataller-Sánchez1, Montserrat Espuña-Pons1, Francisco Carmona-Herrera1.   

Abstract

INTRODUCTION AND HYPOTHESIS: The differential impact of specific pelvic organ prolapse (POP) surgery on sexual activity and function is unknown. Our primary aim was to analyse sexual inactivity and function in women with symptomatic advanced stages of POP and the changes incurred after laparoscopic or vaginal mesh surgery.
METHODS: We performed a secondary analysis of sexual outcomes of a previously published randomised controlled trial comparing laparoscopic sacrocolpopexy/cervicopexy (LSC-Cx) and anterior vaginal mesh (AVM) in 120 women (60/group) with symptomatic anterior POP stage ≥ 3 and apical ≥ 2. Sexual activity and function were assessed preoperatively and 1 and 2 years postoperatively using the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire-IUGA-Revised (PISQ-IR).
RESULTS: Sexual activity was recovered in 42.9% of non-sexually active (NSA) women 1 year postoperatively, mainly in women with higher preoperative POP-related subscale scores of the PISQ-IR, which indicated a negative preoperative sexuality by POP. Recovery of sexual activity was greater after LSC-Cx, albeit not significantly (2 years: 35.5% AVM vs. 45% LSC-Cx). Among sexually active (SA) women preoperatively remaining SA postoperatively, the difference in the mean PISQ-IR summary score significantly improved [mean baseline difference - 2 years; all: 0.3 (95% CI 0.1 to 0.5) p = 0.001; AVM 0.19 (95% CI -0.1 to -0.5) p > 0.05; LSC-Cx 0.37 (95% CI 0.1 to 0.7) p = 0.003]. Preoperative dyspareunia was significantly reduced after LSC-Cx (baseline: 24.6%, 2 years: 9.8%, p = 0.0448), but not after AVM (baseline: 20.7%, 2 years: 18.2%, p = 0.7385).
CONCLUSIONS: Most women reported improved sexual activity and function 2 years after LSC-Cx or AVM, mainly because of enhanced POP-related subscales in both NSA and SA women. Recovery of sexual activity and improved sexual function were greater after LSC-Cx compared to AVM, likely related to less postoperative dyspareunia.

Entities:  

Keywords:  Anterior vaginal mesh; Laparoscopic sacrocolpopexy/cervicopexy; PISQ-IR; Pelvic organ prolapse; Sexual activity; Sexual function

Year:  2020        PMID: 32767064     DOI: 10.1007/s00192-020-04406-1

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  12 in total

1.  An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP).

Authors:  Bernard T Haylen; Christopher F Maher; Matthew D Barber; Sérgio Camargo; Vani Dandolu; Alex Digesu; Howard B Goldman; Martin Huser; Alfredo L Milani; Paul A Moran; Gabriel N Schaer; Mariëlla I J Withagen
Journal:  Int Urogynecol J       Date:  2016-02       Impact factor: 2.894

2.  Laparoscopic sacral hysteropexy versus laparoscopic sacrocolpopexy with hysterectomy for pelvic organ prolapse.

Authors:  Ke Pan; Lili Cao; Nicholas A Ryan; Yanzhou Wang; Huicheng Xu
Journal:  Int Urogynecol J       Date:  2015-07-16       Impact factor: 2.894

3.  Transvaginal repair of stage III-IV cystocele using a lightweight mesh: safety and 36-month outcome.

Authors:  Renaud de Tayrac; Majid Brouziyne; Gérard Priou; Guy Devoldère; Gérard Marie; Joël Renaudie
Journal:  Int Urogynecol J       Date:  2015-03-03       Impact factor: 2.894

4.  Spanish version of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire IUGA-Revised (PISQ-IR): Transcultural validation.

Authors:  Montserrat Mestre; Judith Lleberia; Josep Pubill; Montserrat Espuña-Pons
Journal:  Int Urogynecol J       Date:  2017-04-08       Impact factor: 2.894

5.  Validation of a single summary score for the Prolapse/Incontinence Sexual Questionnaire-IUGA revised (PISQ-IR).

Authors:  Melissa L Constantine; Rachel N Pauls; Rebecca R Rogers; Todd H Rockwood
Journal:  Int Urogynecol J       Date:  2017-06-06       Impact factor: 2.894

6.  Functional and anatomical outcome of anterior and posterior vaginal prolapse repair with prolene mesh.

Authors:  Rodolfo Milani; Stefano Salvatore; Marco Soligo; Paola Pifarotti; Michele Meschia; Marina Cortese
Journal:  BJOG       Date:  2005-01       Impact factor: 6.531

7.  Anatomical outcomes 1 year after pelvic organ prolapse surgery in patients with and without a uterus at a high risk of recurrence: a randomised controlled trial comparing laparoscopic sacrocolpopexy/cervicopexy and anterior vaginal mesh.

Authors:  Eduardo Bataller; Cristina Ros; Sonia Anglès; Miriam Gallego; Montserrat Espuña-Pons; Francisco Carmona
Journal:  Int Urogynecol J       Date:  2018-07-09       Impact factor: 2.894

8.  Analysis of changes in sexual function in women undergoing pelvic organ prolapse repair with abdominal or vaginal approaches.

Authors:  Priyanka Gupta; James Payne; Kim A Killinger; Michael Ehlert; Jamie Bartley; Jason Gilleran; Judy A Boura; Larry T Sirls
Journal:  Int Urogynecol J       Date:  2016-06-24       Impact factor: 2.894

9.  Safety of Vaginal Mesh Surgery Versus Laparoscopic Mesh Sacropexy for Cystocele Repair: Results of the Prosthetic Pelvic Floor Repair Randomized Controlled Trial.

Authors:  Jean-Philippe Lucot; Michel Cosson; Georges Bader; Philippe Debodinance; Cherif Akladios; Delphine Salet-Lizée; Patrick Delporte; Denis Savary; Philippe Ferry; Xavier Deffieux; Sandrine Campagne-Loiseau; Renaud de Tayrac; Sébastien Blanc; Sandrine Fournet; Arnaud Wattiez; Richard Villet; Marion Ravit; Bernard Jacquetin; Xavier Fritel; Arnaud Fauconnier
Journal:  Eur Urol       Date:  2018-02-19       Impact factor: 20.096

10.  Sexual function after robot-assisted prolapse surgery: a prospective study.

Authors:  Femke van Zanten; Cherèl Brem; Egbert Lenters; Ivo A M J Broeders; Steven E Schraffordt Koops
Journal:  Int Urogynecol J       Date:  2018-04-23       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.